JPMorgan lowered the firm’s price target on Sage Therapeutics to $23 from $28 and keeps an Overweight rating on the shares based on the firm’s scenario analysis ahead of the report of data from the SAGE-324 Phase 2b KINETIC 2 trial in essential tremor.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAGE:
- Biotech Alert: Searches spiking for these stocks today
- SAGE Therapeutics Shareholders Back Governance and Incentives
- Sage Therapeutics data ‘head-scratcher and inconclusive,’ says Citi
- Baird views Sage’s SURVEYOR as ‘failed phase 2a study’
- Sage Therapeutics- Phase 2 study in Huntington’s Disease meets primary endpoint